Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial - The Lancet Oncology
Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications - ScienceDirect
ZOMETA (zoledronic acid) for Hypercalcemia of Malignancy and Bone Metastases - Cancer Therapy Advisor
Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases - ScienceDirect
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics - ScienceDirect
Denosumab More Effective than Zometa® in Patients with Bone Metastases - CancerConnect
An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma | Nature Reviews Urology
Modulation of Bone Microenvironment with Zoledronate Enhances the Therapeutic Effects of STI571 and Paclitaxel against Experimental Bone Metastasis of Human Prostate Cancer | Cancer Research
Xgeva: Side effects, cost, dosage, and more
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug | Future Oncology
Less-Frequent Zoledronic Acid in Patients with Bone Metastases - National Cancer Institute
The anti-tumour effects of zoledronic acid - ScienceDirect
/iStock-542310846-59fca08dec2f6400374d5607.jpg "Medications for Treating Bone Metastases From Cancer")
Medications for Treating Bone Metastases From Cancer
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials - Clinical Therapeutics
Zoledronic acid (Zometa) - Oncology Nurse Advisor
Treatment of Multiple Myeloma with Bone Metastasis Focus of Study
IJMS | Free Full-Text | Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer | HTML
Bone health in cancer patients: ESMO Clinical Practice Guidelines† - Annals of Oncology
ZOMETA (zoledronic acid) for Hypercalcemia of Malignancy and Bone Metastases - Cancer Therapy Advisor
ZOMETA (zoledronic acid) for Hypercalcemia of Malignancy and Bone Metastases - Cancer Therapy Advisor
ZOMETA (zoledronic acid) for Hypercalcemia of Malignancy and Bone Metastases - Cancer Therapy Advisor
JCM | Free Full-Text | Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice | HTML
Bone metastases | Nature Reviews Disease Primers
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug | Future Oncology
